Founded in 2020 and based in New York, Deliberate AI is a digital health technology company focused on precision measurement of mental health conditions. The firm builds its platform on multimodal AI and behavioral signal processing, drawing on technical domains including audio analysis, video analysis, natural language processing, and physiological signal analysis.
The company's product suite includes AI-COA, an AI-generated Clinical Outcome Assessment for depression and anxiety; Sophia, a digital health assistant for screening and intake; and Multitude, a tool for biomarker development and clinical trials. Its disease-agnostic platform is designed to serve the psychiatric care, neurological care, and clinical trials sectors.
Deliberate AI has achieved notable regulatory traction: it is the first AI/ML initiative accepted into the U.S. Food and Drug Administration's ISTAND Pilot Program. The company positions its work at the frontier of precision mental health.
